BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)
- Citation:
- Mayo Clin Proc Innov Qual Outcomes vol 5 (6) 1012-1020
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- collection
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 11
- Parents:
- 2751
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Novartis, Genentech/Roche
- Grants:
- U10CA180821, U10CA180882, U10CA180790, UG1CA189825, UG1CA189863, U24CA196171
- Corr. Author:
- Authors:
- Jessica A. Slostad Minetta C. Liu Jacob B. Allred Lori A. Erickson Kandelaria M. Rumilla Matthew S. Block Michael Keppen David King Svetomir N. Markovic Robert R. McWilliams
- Networks:
- IL043, LAPS-MN026, METROMIN, SANFORD
- Study
- NCCTG-N0879
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- cfDNA, cell-free DNA, ddPCR, digital droplet polymerase chain reaction, FFPE, formalin-fixed paraffin-embedded, HR, hazard ratio, LDH, lactate dehydrogenase, MAPK, mitogen-activated protein kinase, NA, not available, NCCTG, North Central Cancer Treatment Group, NPV, negative predictive value, OS, overall survival, PFS, progression-free survival, PPV, positive predictive value